Human single-chain antibodies reactive with native chondroitin sulfate detect chondroitin sulfate alterations in melanoma and psoriasis

Journal of Investigative Dermatology

Volumn 122, Issue 3, 2004, Pages 707-716

  Smetsers, Toon F C M ^a   Van De Westerlo, Els M A ^a   Ten Dam, Gerdy B ^a   Overes, Ingrid M ^a   Schalkwijk, Joost ^a   Van Muijen, Goos N P ^a   Van Kuppevelt, Toin H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Glycosaminoglycan; Monoclonal antibodies; Phage display; Skin disease

Indexed keywords

CHONDROITIN SULFATE; EPITOPE; GLYCOSAMINOGLYCAN; HEPARIN; MONOCLONAL ANTIBODY; POLYSACCHARIDE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CELL SURFACE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MELANOMA; METASTASIS; NEVUS; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PSORIASIS; RAT;

EID: 1842790730     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2004.22316.x     Document Type: Article

References (64)

1. Adany R, Heimer R, Caterson B, Sorrell JM, Iozzo RV: Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates wtth increased PG-40 content and mRNA levels. J Biol Chem 265:11389-11396, 1990
2. Andriessen MP, van den Born J, Latijnhouwers MA, Bergers M, van de Kerkhof PC, Schalkwijk J: Basal membrane heparan sulphate proteoglycan expression during wound healing in human skin. J Pathol 183:264-271, 1997
3. Avnur Z, Geiger B: Immunocytochemical localization of native chondroitin-sulfate in tissues and cultured cells using specific monoclonal antibody. Cell 38:811-822, 1984
4. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M: Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68:729-777, 1999
5. Bernstein EF, Fisher LW, Li K, LeBaron RG, Tan EM, Uitto J: Differential expression of the versican and decorin genes in photoaged and sun-protected skin. Comparison by immunohistochemical and northern analyses. Lab Invest 72:662-669, 1995
6. Bittner M, Meltzer P, Chen Y, et al: Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406:536-540, 2000
7. Calabro A, Midura RJ, Hascall VC, Plaas A, Goodstone NJ, Roden L: Stucture and biosynthesis of chondroitin sulfate and hyaluronan. In: Iozzo RV (ed). Proteoglycans: Structure, Biology and Molecular Interactions: Stucture and Biosynthesis of Chondroitin Sulfate and Hyaluronan. New York: Marcel Dekker, 2000: p 5-26
8. Capila I, Linhardt RJ: Heparin-protein interactions. Angew Chem Int Ed Engl 41:390-412, 2002
9. Caterson B, Christner JE, Baker JR: Identification of a monoclonal antibody that specifically recognizes corneal and skeletal keratan sulfate. Monoclonal antibodies to cartilage proteoglycan. J Biol Chem 258:8848-8854, 1983
10. Caterson B, Christner JE, Baker JR, Couchman JR: Production and characterization of monoclonal antibodies directed against connective tissue proteoglycans. Fed Proc 44:386-393, 1985
11. Caterson B, Griffin J, Mahmoodian F, Sorrell JM: Monoclonal antibodies against chondroitin sulphate isomers: Their use as probes for investigating proteoglycan metabolism. Biochem Soc Trans 18:820-823, 1990a
12. Caterson B, Mahmoodian F, Sorrell JM, et al: Modulation of native chondroitin sulphate structure in tissue development and in disease. J Cell Sci 97 (Part 3):411-417, 1990b
13. Conrad HE: Heparin-Binding Proteins. San Diego, CA: Academic Press, 1998
14. Couchman JR, Caterson B, Christner JE, Baker JR: Mapping by monoclonal antibody detection of glycosaminoglycans in connective tissues. Nature 307:650-652, 1984
15. David G, Bai XM, Van der Schueren B, Cassiman JJ, Van den Berghe H: Developmental changes in heparan sulfate expression: In situ detection with mAbs. J Cell Biol 119:961-975, 1992
16. Deepa SS, Umehara Y, Higashiyama S, Itoh N, Sugahara K: Specific molecular interactions of oversulfated chondroitin sulfate E with various heparin-binding growth factors. Implications as a physiological binding partner in the brain and other tissues. J Biol Chem 277:43707-43716, 2002
17. Denholm EM, Lin Y, Silver PJ: Anti-tumor activities of chondroitinase AC and chondroitinase B: Inhibition of angiogenesis, proliferation and invasion. Eur J Pharmacol 416:213-221, 2001
18. Dennissen MA, Jenniskens GJ, Pieffers M, Versteeg EM, Petitou M, Veerkamp JH, Kuppevelt TH: Large, tissue-regulated, domain diversity of heparan sulfates demonstrated by phage display antibodies. J Biol Chem 277:10982-10986, 2002
19. Dupont E, Savard PE, Jourdain C, et al: Antiangiogenic properties of a novel shark cartilage extract: Potential role in the treatment of psoriasis. J Cutan Med Surg 2:146-152, 1998
20. Elefteriou F, Exposito JY, Garrone R, Lethias C: Binding of tenascin-X to decorin. FEBS Lett 495:44-47, 2001
21. Fernandez-Botran R, Yan J, Justus DE: Binding of interferon gamma by glycosaminoglycans: A strategy for localization and/or inhibition of its activity. Cytokine 11:313-325, 1999
22. Folberg R, Pe'er J, Gruman LM, et al: The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: A matched case-control study. Hum Pathol 23:1298-1305, 1992
23. Geiser M, Schultz D, Le Cardinal A, Voshol H, Garcia-Echeverria C: Identification of the human melanoma-associated chondroitin sulfate proteoglycan antigen epitope recognized by the antitumor monoclonal antibody 763.74 from a peptide phage library. Cancer Res 59:905-910, 1999
24. Hemming FJ, Pays L, Soubeyran A, Larruat C, Saxod R: Development of sensory innervation in chick skin: Comparison of nerve fibre and chondroitin sulphate distributions in vivo and in vitro. Cell Tissue Res 277:519-529, 1994
25. Hurt-Camejo E, Rosengren B, Sartipy P, Elfsberg K, Camejo G, Svensson L: CD44, a cell surface chondroitin sulfate proteoglycan, mediates binding of interferon-gamma and some of its biological effects on human vascular smooth muscle cells. J Biol Chem 274:18957-18964, 1999
26. Jenniskens GJ, Oosterhof A, Brandwijk R, Veerkamp JH, van Kuppevelt TH: Heparan sulfate heterogeneity in skeletal muscle basal lamina: Demonstration by phage display-derived antibodies. J Neurosci 20:4099-4111, 2000
27. Jenniskens GJ, Koopman WJ, Willems PH, Pecker I, Veerkamp JH, Van Kuppevelt TH: Phenotypic knockout of heparan sulfates in myotubes impairs excitation-induced calcium spiking. FASEB J, 17:878-880, 2003
28. Kaplan M, Aviram M: Macrophage plasma membrane chondroitin sulfate proteoglycan binds oxidized low-density lipoprotein. Atherosclerosis 149:5-17, 2000
29. Karamanos NK, Hjerpe A, Aletras A, Tsegenidis T, Anastassiou ED, Antonopoulos CA: Antibodies to three chondroitin sulfate-containing proteoglycans in squid skin recognize hexa-or longer chondroitin oligosaccharides as major antigenic determinants. Arch Biochem Biophys 316:100-109, 1995
30. Kumar S, Li C: Targeting of vasculature in cancer and other angiogenic diseases. Trends Immunol 22:129, 2001
31. Lee CM, Tanaka T, Mural T, et al: Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res 62:4282-4288, 2002
32. Lindahl U, Kusche-Gullberg M, Kjellen L: Regulated diversity of heparan sulfate. J Biol Chem 273:24979-24982, 1998
33. Manten-Horst E, Danen EH, Smit L, et al: Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential. Int J Cancer 64:182-188, 1995
34. Martins JR, Gadelha ME, Fonseca SM, Sampaio LO, De LPPA, Dietrich CP, Nader HB: Patients with head and neck tumors excrete a chondroitin sulfate with a low degree of sulfation: A new tool for diagnosis and follow-up of cancer therapy. Otolaryngol Head Neck Surg 122:115-118, 2000
35. Nissim A, Hoogenboom HR, Tomlinson IM, Flynn G, Midgley C, Lane D, Winter G: Antibody fragments from a "single pot" phage display library as immunochemical reagents. EMBO J 13:692-698, 1994
36. Park CC, Bissell MJ, Barcellos-Hoff MH: The influence of the microenvironment on the malignant phenotype. Mol Med Today 6:324-329, 2000
37. Pluschke G, Vanek M, Evans A, et al: Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci USA 93:9710-9715, 1996
38. Ricciardelli C, Mayne K, Sykes PJ, et al: Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. Clin Cancer Res 3:983-992, 1997
39. Ricciardelli C, Quinn DI, Raymond WA, et al: Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Res 59:2324-2328, 1999
40. Sauder DN, Dekoven J, Champagne P, Croteau D, Dupont E: Neovastat (AE-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis. J Am Acad Dermatol 47:535-541, 2002
41. Schonherr E, Beavan LA, Hausser H, Kresse H, Culp LA: Differences in decorin expression by papillary and reticular fibroblasts in vivo and in vitro. Biochem J 290 (Part 3):893-899, 1993
42. Seyger MM, van den Born J, Schalkwijk J, van de Kerkhof PC, de Jong EM: Altered distribution of heparan sulfate proteoglycans in psoriasis. Acta Derm Venereol 77:105-109, 1997
43. Smetsers TFCM, van de Westerlo E, ten Dam GB, et al: Localization and characterization of melanoma-associated glycosaminoglycans: Differential expression of chondroitin and heparan sulfate epitopes in melanoma. Cancer Res 63:2965-2970, 2003
44. Sorrell JM, Mahmoodian F, Schafer IA, Davis B, Caterson B: Identification of monoclonal antibodies that recognize novel epitopes in native chondroitin/dermatan sulfate glycosaminoglycan chains: Their use in mapping functionally distinct domains of human skin. J Histochem Cytochem 38:393-402, 1990
45. Sorrell JM, Carrino DA, Caplan AI: Structural domains in chondroitin sulfate identified by anti-chondroitin sulfate monoclonal antibodies. Immunosequencing of chondroitin sulfates. Matrix 13:351-361, 1993
46. Sorrell JM, Carrino DA, Baber MA, Asselineau D, Caplan AI: A monoclonal antibody which recognizes a glycosaminoglycan epitope in both dermatan sulfate and chondroitin sulfate proteoglycans of human skin. Histochem J 31:549-558, 1999
47. Taipale J, Keski-Oja J: Growth factors in the extracellular matrix. FASEB J 11:51-59, 1997
48. Theocharis AD, Tsara ME, Papageorgacopoulou N, Karavlas DD, Theocharis DA: Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. Biochim Biophys Acta 1502:201-206, 2000
49. Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G: The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J Mol Biol 227:776-798, 1992
50. Touab M, Villena J, Barranco C, Arumi-Uria M, Bassols A: Versican is differentially expressed in human melanoma and may play a role in tumor development. Am J Pathol 160:549-557, 2002
51. Touab M, Arumi-Uria M, Barranco C, Bassols A: Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi. Am J Clin Pathol 119:587-593, 2003
52. Tumova S, Woods A, Couchman JR: Heparan sulfate proteoglycans on the cell surface: Versatile coordinators of cellular functions. Int J Biochem Cell Biol 32:269-288, 2000
53. Turnbull JE, Hopwood JJ, Gallagher JT: A strategy for rapid sequencing of heparan sulfate and heparin saccharides. Proc Natl Acad Sci USA 96:2698-2703, 1999
54. van de Westerlo E, Smetsers TFCM, Denniesen MABA, Linhardt J, Veerkamp JH, van Muijen GNP, van Kuppevelt TH: Human single chain antibodies against heparin: Selection, characterization and effect on coagulation. Blood 99:2427-2433, 2002
55. van den Born J, Gunnarsson K, Bakker MA, et al: Presence of N-unsubstituted glucosamine units in native heparan sulfate revealed by a monoclonal antibody. J Biol Chem 270:31303-31309, 1995
56. van Kuppevelt TH, Dennissen MA, van Venrooij WJ, Hoel RM, Veerkamp JH: Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem 273:12960-12966, 1998
57. Venkataraman G, Shriver Z, Raman R, Sasisekharan R: Sequencing complex polysaccharides. Science 286:537-542, 1999
58. Verschoore M, Kowalewski C, Chorzelska MJ, Bernard BA, Darmon YM: Intraepidermal leakage of plasma proteins after tape stripping of normal skin and uninvolved psoriatic skin. Br J Dermatol 122:391-397, 1990
59. Wells AF, Lundin A, Michaelsson G: Histochemical localization of hyaluronan in psoriasis, allergic contact dermatitis and normal skin. Acta Derm Venereol 71:232-238, 1991
60. Willen MD, Sorrell JM, Lekan CC, Davis BR, Caplan AI: Patterns of glycosaminoglycan/proteoglycan immunostaining in human skin during aging. J Invest Dermatol 96:968-974, 1991
61. Yamagata M, Kimata K, Oike Y, et al: A monoclonal antibody that specifically recognizes a glucuronic acid 2-sulfate-containing determinant in intact chondroitin sulfate chain. J Biol Chem 262:4146-4152, 1987
62. Yamori T, Ota DM, Cleary KR, Irimura T: Increased content of chondroitin sulfate proteoglycan in human colorectal carcinoma metastases compared with the primary tumor as determined by an anti-chondroitin-sulfate monoclonal antibody. J Cell Biochem 36:405-416, 1988
63. Zimmermann DR, Dours-Zimmermann MT, Schubert M, Bruckner-Tuderman L: Versican is expressed in the proliferating zone in the epidermis and in association with the elastic network of the dermis. J Cell Biol 124:817-825, 1994
64. Zou K, Muramatsu H, Ikematsu S, et al: A heparin-binding growth factor, midkine, binds to a chondroitin sulfate proteoglycan, PG-M/versican. Eur J Biochem 267:4046-4053, 2000